Cirrhosis of the liver and chronic hepatitis have been treated by fetal precursor cell transplantation with success for the last four decades.
After extensive experimental work, a treatment of heart attack by cell transplantation was introduced by cardiologists into clinical practice.
There are many German publications to confirm value of fetal precursor cell therapy in the treatment of incurable liver diseases.
Cirrhosis of liver and chronic hepatitis were very common in Germany in 40 – 50 – 60 – ies. This was a result of severe epidemic of viral hepatitis in Germany during WW2 and thereafter.
Since even today there is no effective therapy for damaged liver, fetal precursor cell therapy became a treatment of choice for such serious liver diseases.
Such patients can be helped unless their disease has advanced into the stage of portal hypertension (edema, ascites, bleeding esophageal varices, etc.).
If chronic alcoholism is the cause of liver cirrhosis, cell transplantation would be of value only with a total abstinence.
For patients with chronic hepatitis it is mandatory to suppress an inflammatory process in the liver first, by all other therapeutic means. With such approach the success of fetal precursor cell transplantation can be unexpectedly high.
During last two years several patients with recent extensive myocardial infarction were treated by cell transplantation in various western European countries with uniformly good results. It is reported in “Handbook of Cardiovascular Cell Transplantation”, published in 2004 by Martin Dunitz, a U.K. publisher.
The purpose is to:
- regenerate as many damaged heart muscle fibers as possible, and thereby decrease the size of myocardial scar, as well as
- stimulate angiogenesis, i.e. forming new blood vessels from the pre-existing ones
For patients with massive heart attacks it is a matter of life or death, or a matter of debilitating disability versus ability to live reasonably well.
Stem cell transplants have to be implanted also into heart, although not necessarily directly into heart muscle. They can be implanted into re-opened obstructed branch of coronary artery, or into infarcted heart muscle via angiographic approach.
According to U.S. statistics 1.1 million Americans gets heart attack every year. And there is 4.8 million of patients with congestive heart failure, of which over one half dies within 5 years.
The existing treatments of all degenerative diseases suffer from one common problem: no attempt at regeneration of degenerating cells of diseased organs and tissues is made. The sole treatment available to medicine today to directly regenerate cells, tissues and organs is fetal precursor cell transplantation.
Most of known degenerative diseases have been treated with success by fetal precursor cell transplantation.
All such patients should be candidates for cell transplantation.